Rebensburg Stephanie, Helfer Markus, Schneider Martha, Koppensteiner Herwig, Eberle Josef, Schindler Michael, Gürtler Lutz, Brack-Werner Ruth
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt, Institute of Virology, Oberschleißheim.
Ludwig Maximilian's University, Max von Pettenkofer Institute, Munich.
Sci Rep. 2016 Feb 2;6:20394. doi: 10.1038/srep20394.
Novel therapeutic options are urgently needed to improve global treatment of virus infections. Herbal products with confirmed clinical safety features are attractive starting material for the identification of new antiviral activities. Here we demonstrate that Cistus incanus (Ci) herbal products inhibit human immunodeficiency virus (HIV) infections in vitro. Ci extract inhibited clinical HIV-1 and HIV-2 isolates, and, importantly, a virus isolate with multiple drug resistances, confirming broad anti-HIV activity. Antiviral activity was highly selective for virus particles, preventing primary attachment of the virus to the cell surface and viral envelope proteins from binding to heparin. Bioassay-guided fractionation indicated that Ci extract contains numerous antiviral compounds and therefore has favorably low propensity to induce virus resistance. Indeed, no resistant viruses emerged during 24 weeks of continuous propagation of the virus in the presence of Ci extracts. Finally, Ci extracts also inhibited infection by virus particles pseudotyped with Ebola and Marburg virus envelope proteins, indicating that antiviral activity of Ci extract extends to emerging viral pathogens. These results demonstrate that Ci extracts show potent and broad in vitro antiviral activity against viruses that cause life-threatening diseases in humans and are promising sources of agents that target virus particles.
迫切需要新的治疗方法来改善全球病毒感染的治疗状况。具有已确认临床安全性特征的草药产品是鉴定新抗病毒活性的有吸引力的起始材料。在此，我们证明白藓（Ci）草药产品在体外可抑制人类免疫缺陷病毒（HIV）感染。Ci提取物可抑制临床HIV-1和HIV-2分离株，重要的是，还能抑制一种具有多重耐药性的病毒分离株，证实了其广泛的抗HIV活性。抗病毒活性对病毒颗粒具有高度选择性，可阻止病毒与细胞表面的初始附着以及病毒包膜蛋白与肝素的结合。生物测定指导的分级分离表明，Ci提取物含有多种抗病毒化合物，因此诱导病毒耐药的倾向较低。实际上，在病毒与Ci提取物共同连续传代24周的过程中未出现耐药病毒。最后，Ci提取物还可抑制用埃博拉病毒和马尔堡病毒包膜蛋白假型化的病毒颗粒的感染，这表明Ci提取物的抗病毒活性可扩展至新兴病毒病原体。这些结果表明，Ci提取物对在人类中引起危及生命疾病的病毒具有强大且广泛的体外抗病毒活性，是靶向病毒颗粒药物的有前景来源。
